Abstract Body

Background: WHO guidelines for patients on antiretroviral therapy (ART) recommend immunologic monitoring when viral load (VL) testing is not available. In sub-Saharan Africa immunologic monitoring is neither sensitive nor specific and leads to switching to second-line regimens that are more costly than first-line ART. We sought to determine if VL testing in patients suspected of immunologic failure was cost-saving. Methodology: We reviewed the records of patients who had VL testing prior to ART switching as recommended by the existing program in 7 governmentrun urban clinics in Kampala, between October 2008 and October 2011. VL testing was performed in an unsubsidized central lab facility where the cost of a VL test is $62. The cost of first-line ART averaged $14.68 per person per month and second-line ART, $35.99 per person per month. Results: 312 patients were tested at 7 clinics in Kampala City. 185 (59%) had detectable VL (>400 copies/mL) and 127(41%) had undetectable VL (< 400 copies). Of the 185 with detectable VL, 24 had 5000 (51.6%) were switched to second-line while 151 patients with VL < 5000 (48.4%) remained on first-line therapy. The cost of targeted VL testing in patients with immunologic failure was recouped in 6.0 months when compared to the increased cost of treating patients who had immunologic failure but suppressed VL with the second line regimen as indicated in table 1 Conclusions: Testing with VL prevents the unnecessary switching to second-line ART in 50% of patients and recouping of the cost of VL testing in those who immunologically fail at 6.0 months.